Sentences with phrase «pharma companies on»

A lot of commenters have been expecting that challenge to turn into more money spent by pharma companies on biotech; but the Abbott - Piramal transaction emphasized that there's more than one way... [more]

Stewart Perry, Alison Dennis and Jonathan Brooks are mentioned in «Fieldfisher advises administrators of listed pharma company on ground - breaking IP disposal»

Not exact matches

On average, the 30 large and small pharmaceutical and biotech companies IDEA Pharma examined got just 11 % of their 2017 revenue from drugs developed within the past five years, says Mike Rea, the firm's CEO and one of the most insightful people I've met — no exaggeration — when it comes to pinpointing innovation choke points in the drug industry.

-- Ahmed Albaiti, founder and CEO of Medullan, a digital health innovation company that works with payers, providers, and pharma on patient engagement.

Big biotech and pharma companies are absolutely dependent on being able to successfully innovate by partnering with and acquiring disruptive startups because of the nature of the patent cliff in pharmaceuticals.

The company runs clinical studies on behalf of its multinational pharma clients in oncology, respiratory / infectious disease and central nervous system disorders.

Martin Shkreli, unaffectionately known as the «pharma bro» — and infamous for his decision to hike the list price of Daraprim, a drug used by HIV / AIDS and cancer patients to combat infections, by more than 5,000 % in 2015 under his former company Turing Pharmaceuticals — was convicted on three criminal securities fraud and conspiracy charges by a Brooklyn jury on Friday.

«On Nasdaq, the main investors for biotech stocks are mainly U.S. funds, but, in Hong Kong, we can better tap Chinese and Asian investors as we are closer to them,» said Yang Dajun, chairman of Ascentage Pharma, a Chinese biotech company.

But it appears that CEO and founder Jean - Paul Clozel just isn't too keen on selling the company he's built, leading the U.S. pharma giant to walk away from the negotiating table and its $ 20 billion offer.

Valeant CEO Mike Pearson said in a conference call that Medicis will strengthen the company's place in medical dermatology and bring it to critical mass in aesthetics, a $ 12 - billion market that doesn't depend on government health - plan reimbursement and previously did not have a significant «big pharma» presence.

That's leaving entire areas open for the taking and Valeant — a specialty pharma company that focuses on dermatology, ophthalmology and over-the-counter medications — which already has a strong foothold in emerging markets is poised to fill that void.

Fortune spoke with 25 - year pharmaceutical vet Ramona Sequeira, president of Takeda's U.S. business unit since 2015, on the challenges of adapting an international pharma company to the U.S. healthcare and reimbursement system and the firm's America - centric business plans.

Pharma is generally proud of its diversity: A few days before the Trump enacted the ban, J&J published on its website the story of employee Abdullah Al Hommada, who fled his native Syria for the Netherlands and now works at the company's Janssen division.

With few competitors on the market, the pharma company reportedly planned on even steeper hikes to the price, figuring that a combination of customers» insurance coverage and discounts the company provides to patients would offset the increases.

This can set you up also for more long term reputation rehabilitation by forcing a focus on Turing as a research and development company — not a pharma hedge fund hybrid.»

Today, at 2 p.m. Eastern, the President will sign the 21st Century Cures Act — approved by the Senate on Dec. 7 by a vote of 94 - to - 5, overwhelmingly passed by the House the week before, and seemingly supported by every pharma company, medical institution, healthcare advocate and their mothers.

And the tactic isn't all that surprising: big pharma's return on R&D investments has been plummeting over the last decade, and price increases are an easy way to bolster companies» bottom lines.

The latest pharma innovation report from Deloitte holds some pretty grim news for pharma: returns on R&D investments by large cap companies slid to a mere 3.7 % in 2016, down from the 10.1 % returns seen in 2010 (although the cost of bringing a drug to market is beginning to stabilize).

By printing multiple lung airways — or any other afflicted organ — from a human patient and testing drugs on them, pharma companies can bypass the ethically challenged practice of testing on animals and proceed to human clinical trials with greater confidence the drugs will actually work, according to Wadsworth.

Biotech giant Gilead Sciences is beefing up its cancer drug portfolio with a $ 11.9 billion deal to buy Kite Pharma, a company focused on a groundbreaking new class of treatments that turns the body's own immune cells into targeted blood cancer killers.

Insurers have been striking deals with pharma companies that will land them discounts on pricey drugs if those treatments don't demonstrably improve patients» health outcomes; hospitals are penalized if they have high rates of patient readmissions.

Jazz said in a filing that it did so in response to the overall takeover environment for pharma companies and in light of a patent litigation settlement that allows Hikma Pharmaceuticals to sell a generic version of Xyrem with Jazz receiving royalty payments on those sales.

In its first year of business, Sun Pharma generated more than $ 100,000 in sales, and in 1994 the company went public on the Bombay Stock Exchange.

The race to become the first company with a chimeric antigen receptor T - cell (CAR - T) cancer therapy on the market has entered its final leg, and Kite Pharma now appears to have a big advantage.

The spirited pharma - tech entrepreneur, known for her liberal use of the color pink and for the $ 1B sale of her female sexual health company, is laser - focused on helping female entrepreneurs flourish.

Pharma veteran created a company that delivers prescription medications to you for free, on the same day.

During an event in Manchester, New Hampshire, on Monday, President Donald Trump asked a top executive from Adapt Pharma Inc. to join him on stage and handed him the microphone to talk about the company's programs that provide free and discounted samples of its Narcan spray to schools and first responders.

The hemp bill Mitch McConnell just introduced is likely to pass and is going to give huge pharma companies the opportunity to come in and «steal» CBD from existing producers through hemp laws categorizing the plant based on THC levels instead of what matters: growing methods and harvested materials.

On Monday, United Therapeutics reached a deal to acquire Israel - based SteadyMed Therapeutics Inc. in a deal potentially valued at US$ 216mln, a move that eliminates a serious competitive threat to the Maryland biotech by literally pulling the speciality pharma company into its own corner.

Large companies (Big Pharma) spend considerable amounts on advertising and distribution, and often have large sales forces that promote their drugs to physicians to convince them to prescribe the drug.

Drug companies became a favorite villain during the presidential campaign when Democratic candidates Hillary Clinton and Bernie Sanders beat on «Pharma Bro» Martin Shkreli for raising a drug price 5,000 %.

The HHS secretary went on to say that his agency wanted to find ways for Medicaid and Medicare to bring drug prices down by creating more resources to negotiate with pharma companies.

While Williams built his reputation on deals such as the merger of fertiliser giants Incitec and Pivot and more recently by advising Bega Cheese in the takeover battle of Warrnambool Cheese & Butter, he has dabbled in small pharma companies for years.

«As a global company on the forefront of healthcare change, Astellas is proud to once again be a part of bringing international rugby back to Chicago, a great sporting city and the headquarters for Astellas in the Americas,» said James Robinson, president, Astellas Pharma US.

Common Cause says the Moreland Commission should open a probe to see if there's a link between around $ 5 million spent by major pharmaceutical companies on lobbying and campaign donations to New York state politicians, and the failure to pass major consumer - friendly bills regulating Big Pharma.

The technology is allowing basic scientists and small companies to generate impressive libraries of molecules, on a scale once reserved for big pharma, and select from them the most useful compounds.

Backed by an extensive offering of premium laboratory instruments, consumables and services, the LPS division concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those in academic research institutes.

The intention of the pharma industry postdoc, he advises, should be to get the industry experience and then move on to another company.

Or how much a possible acquisition target is worth (just read up on all the mergers that have been going on lately in pharma, and you'll understand why companies need financial analysts «in house»).

On the plus side, Mark Citron, vice president of clinical and regulatory affairs at TyRx Pharma in Monmouth Junction, New Jersey, a combination cardiac device manufacturer, says it's much easier for entry - level scientists to find jobs at MD&D companies.

Focused on the prospect of jobs at biotech and pharma companies, many life scientists overlook MD&D — a field that, though perhaps currently less lucrative than those better known industries, is also easier to enter for early - career life scientists.

Not only are biotech companies loosening pharma's stronghold on small molecules, but pharma is, increasingly, forging biotech research alliances.

For example, if you and your fellow postdocs would like to learn about career opportunities in industry and biotech, you'll need to invite a variety of companies focusing on areas ranging from clinical trials to biotech start - ups to big pharma.

Another area that big pharma has traditionally been reluctant to get involved with is research into orphan diseases — ones that affect so few people that working on them is not usually considered commercially viable by large companies.

(Stern also sits on a health and safety committee of the NFL Players Association and is a consultant to pharma companies.

The new tests were led by Santaris Pharma, a biotech company in Horsholm, Denmark, focused on developing microRNA - based therapies.

From 1997 - 2008, Joern was President and CEO of Evotec AG, where he designed many alliances with leading pharma and biotech companies, listed the Company on the Frankfurt Stock Exchange and NASDAQ, and managed the acquisition of LSE - listed Oxford Asymmetry and NASDAQ - listed Renovis Inc..

Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions

He is the President and Founder of Noventia Pharma Specialty Pharma, a European - based company he founded in 2009 that is focused on the research of rare and neglected diseases.

Massimo holds a Ph.D. from the University of Milan, where he graduated with honors, and currently serves on the boards of various companies such as Bioakos Pharma, Arriani International and Ariad Pharmaceuticals.